Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £45,600 - £55,000 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Research Group Leader, ICR Clinical Trials and Statistics Unit (ICR-CTSU)

  • Sutton
  • Clinical Trials and Statistics Unit
  • Salary: From £66,092 pa
  • Permanent

Role Summary The Group Leader will lead a component of ICR-CTSU’s portfolio of clinical trials research. The post holder will further develop and grow the portfolio in line with ICR-CTSU’s overall strategy and take responsibility for a number of ongoing trials as well as the development of new trials. We seek an experienced biostatistician with a strong research interest in clinical trials methodology and a passion for direct involvement in the oversight and leadership of academic clinical trials. The successful candidate will work closely with the Director of ICR-CTSU to further enhance the Unit’s internationally recognised strength in clinical trial design, conduct and analysis. The post holder will be expected to make a substantial independent intellectual contribution to clinical trials projects and be proactive in leading and contributing to broad initiatives that enhance the overall effectiveness of ICR-CTSU. The appointee will contribute to the overall scientific life of the ICR including the newly established ICR/Royal Marsden Hospital’s Centre for Trials and Population Data Science, by providing mentorship to more junior colleagues and acting as an academic leader. We seek an individual who will work closely and collaboratively with other faculty/Group Leaders at ICR and with international/national key opinion leaders to extend the breadth and depth of ICR-CTSU’s biologically rich clinical trials portfolio. In partnership with clinical opinion leaders, s/he will generate research funds to conduct and deliver clinical trials research at the international forefront. Presentation at national and international conferences, production of top-quality research outputs and substantial professional contribution to wider clinical trial network bodies are expected. Enthusiasm for team-based science in a collaborative interdisciplinary environment is essential. The appointment will be based on track record and the ability and willingness to engage in team science. The successful appointee will have access to ICR’s successful PhD training programme and core facilities. Key Requirements Higher degree (MSc or PhD) in medical statistics/biostatistics or an allied field (e.g. public health, epidemiology, data science) with relevant work experience Significant experience as a clinical trials, medical or bio-statistician within the academic or commercial sector A desire to apply existing and novel statistical methods to the requirements of a diverse range of statistical problems A broad understanding of cancer research Ability to lead a Clinical Trials Unit based research group As part of your online application, you will be required to upload your full CV which will pre-populate your application form, you will also be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: Lists of major publications, achievements, research grants and distinctions. A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity or a single document giving hyperlinks to these outputs. You must also complete the personal statement section of the application form in the format of a cover letter including the names and contact details of three academic referees Department/Directorate Information: Division of Clinical Studies Clinical Trials and Statistics Unit (ICR-CTSU) The ICR-CTSU is a Cancer Research UK-funded, internationally recognised methodologist led clinical trials unit, providing cancer-focused clinical trial research expertise. We lead pioneering, efficient, high-quality, and impactful trials across the phases. Our expertise ranges from experimental medicine early phase studies exploring biological efficacy to trials which may deliver widespread change to routine practice, underpinned by applied methodology to drive forward clinical trial innovation. See our clinical trials Joining as a group leader, you will be given outstanding support to help you to continue to develop in your career. Along with a start-up package of funding, you will also have access to resources to establish your group, including support for recruiting key group members, such as PhD students and postdoctoral researchers. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Emma Hall ([email protected])

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

11/07/25

Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread through the body. 

A team of researchers from The Institute of Cancer Research, London, has identified that a protein called SLC7A11 protects melanoma cells from damage as they pass through stressful environments in the body – allowing them to grow and spread unchecked.

The findings could open new avenues of research to disable the disease’s defences, offering fresh hope for thousands of patients.

The discovery, published in the journal Cell Reports, could also lead to new tests to spot these aggressive tumours.

Shielding cells from damage

Normally, cells are vulnerable to a process called oxidative stress – a kind of internal ‘rusting’ that damages and destroys them.

In research funded by Cancer Research UK, UK Research and Innovation (UKRI), Worldwide Cancer Research, Breast Cancer Now and Barts Charity, the team grew melanoma tumours in the lab. They saw that the more aggressive cells in the tumour – those around the border, with a rounder shape which enables them to invade other tissues – produced high amounts of the protein SLC7A11, which protects against oxidative stress.

They found that SLC7A11 acts not only as a protective shield against oxidative stress, but also as a suit of armour, controlling the cytoskeleton of the cancer cells – a structure that helps them become mobile and aggressive. When they knocked out the protein and stopped it from working, the cells were less round, and less able to grow and invade.

Blocking the ‘suit of armour’ protein

The team treated the melanoma tumours in the lab with drugs that inhibit SLC7A11 – after 72 hours, almost 75 per cent of the cells had died.

The ICR researchers hope that targeted SLC7A11 inhibitors can be developed in the future and trialled for the treatment of melanoma.

The role of antioxidants

Oxidative stress is a process that can be counteracted with antioxidants. The team found that when they treated the melanoma cells with the antioxidant glutathione, the cells became rounder – the more aggressive shape.

The antioxidant even protected the cells from damage caused by oxidative stress when the SLC7A11 protein was knocked out.

Antioxidant supplements have become popular and can be bought over the counter. The researchers therefore urge caution for patients with melanoma when taking any antioxidant supplements that could contain larger doses than recommended by health organisations.

The ICR – which is both a research institute and a charity – is helping more people survive melanoma skin cancer. Give a monthly donation to help us uncover how melanoma develops, grows and spreads – so we can develop new treatments to stop it in its tracks, and save more lives. 

Please donate today

‘A warning sign’

Professor Victoria Sanz-Moreno, Professor of Cancer Cell and Metastasis Biology at The Institute of Cancer Research, London, who led the study said:

“Our study has helped us to better understand how some cancer cells protect themselves from the stresses they encounter as they attempt to spread around the body. This could lead to new ways to identify and treat aggressive melanoma.

“High levels of the SLC7A11 protein seems to be a warning sign that a tumour is likely to spread. We have shown in the lab that targeting this protein leaves the cancer cells exposed and vulnerable to oxidative stress, blocking their ability to invade other tissues.

“If we take away the melanoma cells’ shield and armour, we could stop cancer in its tracks.

“Importantly, we’ve also shown that even if you remove the shield and armour, antioxidants can boost the aggressive nature of melanoma cells. We therefore urge caution when taking these over-the-counter supplements.”

‘New lines of attack against melanoma’

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said:

“We know that cancer is most deadly once it has spread. Finding ways to stop cancer from spreading around the body is crucial to give patients more time living well. I hope this research opens the door to new lines of attack against melanoma in the future.”

‘Complex relationship between antioxidant supplements and cancer’

Dr Dani Edmunds, Research Information Manager at Cancer Research UK, said:

“Once cancer starts spreading, treatment options become more limited. The earlier we can stop it from spreading, the better the chances of long-term survival.  

“It’s promising to see that melanoma skin cancer could be stopped from spreading by stripping away its defences. While this is early-stage research, future clinical trials could help us understand how this approach works in the body and how best we can use it to save and improve lives.

“This research also highlights the complex relationship between antioxidant supplements and cancer. We know that eating a healthy balanced diet can help to reduce the risk of cancer. If you have been diagnosed with cancer, we strongly advise talking to your doctor before taking any over-the-counter health supplements.”